SCHEMBL9907459

SCHEMBL9907459

Cc1cc(C(=O)O)cc2c(-c3ccc(Cl)cc3Cl)ccnc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 2/20 0.45
SRD5A2 P31213 1/20 0.43
KDM5B Q9UGL1 1/20 0.42
ALPL P05186 1/20 0.41
CRHR1 P34998 2/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
NPC1 O15118 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
F2RL3 Q96RI0 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CRHBP P24387 1/20 0.39
RAB9A P51151 1/20 0.39
CRHR2 Q13324 1/20 0.39
MARS1 P56192 1/20 0.38
RARA P10276 1/20 0.37
RARB P10826 1/20 0.37
RARG P13631 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907512 0.91 KDM4C (0.47) KDM4CSRD5A2KDM5BMRGPRX4KDM4E
SCHEMBL9907495 0.90 PTGDR2 (0.41) KDM4CKDM5BALPLMRGPRX4RARA
SCHEMBL9907428 0.88 MAPK14 (0.43) KDM4CKDM5B
SCHEMBL9907490 0.88 KMO (0.48) KDM4CKDM5BMRGPRX4
SCHEMBL9907455 0.87 ALPL (0.44) ALPLCRHR1MRGPRX4NPC1F2RL3
SCHEMBL9909228 0.86 KDM5A (0.43) KDM4CKDM5BMRGPRX4SMN1; SMN2KDM4E
SCHEMBL9909167 0.86 CCNT1 (0.42) KDM4CKDM5BMRGPRX4KDM4E
SCHEMBL9907827 0.84 SLC9A1 (0.42)
SCHEMBL9907452 0.81 CTSA (0.42) KDM4CKDM5BMRGPRX4
SCHEMBL9907464 0.81 PTGDR2 (0.46) MRGPRX4RARGMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-B1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC (JP) 2014-03-12 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E KDM4C 1366/4885SRD5A2 509/4885KDM5B 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.